Author

B. Bui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Beck· 1 shared C. Chevreau· 1 shared C. K. Petritsch· 1 shared C. Merle· 1 shared D. Hambardzumyan· 1 shared D. Panovska· 1 shared D. Ranchere-Vince· 1 shared E. Darbo· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Beck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma

Y. L. Xing, D. Panovska, J.-W. Park, S. Grossauer, K. Koeck, B. Bui, E. Nasajpour, J. J. Nirschl, Z.-P. Feng, P. Cheung, P. Habib, R. Wei, J. Wang, W. Thomason, J. Xiu, , C. K. Petritsch

This study shows that BRAF/MEK inhibition induces cell state transitions in BRAFV600E-mutant gliomas, leading to PD-L1 upregulation and immune evasion, which can be overcome by combining with immune checkpoint inhibition.

bioRxiv · Feb 3, 2023Cancer Biology

Distinct cellular origins and differentiation process account for distinct oncogenic and clinical behaviors of leiomyosarcomas

E. Darbo, G. Perot, L. Darmusey, S. Le Guellec, L. Leroy, L. Gaston, N. Desplat, N. Thebault, C. Merle, P. Rochaix, T. Valentin, G. Ferron, C. Chevreau, B. Bui, E. Stoeckle, , F. Chibon

The paper identifies a transcriptionally homogeneous subgroup of leiomyosarcomas originating from vascular smooth muscle cells and explains their unique oncogenic behavior through specific pathway alterations.

bioRxiv · Oct 23, 2020Cancer Biology